Quoin Pharmaceuticals Ltd.
QNRX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001671502
In the last 90 days, Quoin Pharmaceuticals Ltd. insiders filed 4 open-market purchases and 0 sales; 19 institutions reported holding it in 13F filings for Q2 2026, worth $6.29M in total; no superinvestor holds it.
13F holders, Q1 2026
Institutional positions in Quoin Pharmaceuticals Ltd. as of Mar 31, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 21
- +3 vs. Q4 2025
- Shares held
- 1.18M
- +341.9K (+40.6%) vs. Q4 2025
- Total value
- $7.82M
- −$4.34M (−35.7%) vs. Q4 2025
- New holders
- 6
- 7 more added
- Sold out
- 3
- 4 more reduced
Compare with Q4 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting QNRX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 19 | $6.29M |
| Q1 2026 | 21 | $7.82M |
| Q4 2025 | 18 | $12.2M |
| Q3 2025 | 4 | $10.7K |
| Q2 2025 | 6 | $23.4K |
| Q1 2025 | 10 | $90.2K |
| Q4 2024 | 14 | $1.01M |
| Q3 2024 | 7 | $82.2K |
| Q2 2024 | 10 | $127.7K |
| Q1 2024 | 8 | $183.2K |
| Q4 2023 | 3 | $105.6K |
| Q3 2023 | 3 | $7.21K |
| Q2 2023 | 2 | $24.0K |
| Q1 2023 | 4 | $81.1K |
| Q4 2022 | 4 | $52.0K |
| Q3 2022 | 7 | $272.0K |
| Q2 2022 | 8 | $321.0K |
| Q1 2022 | 6 | $419.0K |
| Q4 2021 | 7 | $383.0K |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2026
Shares, value and share of portfolio for each institution holding Quoin Pharmaceuticals Ltd.; share changes are against Q4 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ikarian Capital, LLC | 211,538 | $1.40M | 0.20% | 00.0% | Unchanged |
| Dauntless Investment Group, LLC | 196,592 | $1.30M | 3.65% | +196,592 | New |
| SummitTX Capital, L.P. | 100,300 | $662.0K | 0.02% | +35,505+54.8% | Added |
| Velan Capital Investment Management LP | 84,849 | $560.0K | 0.35% | +84,849 | New |
| Woodline Partners LP | 79,582 | $525.2K | 0.00% | 00.0% | Unchanged |
| Millennium Management LLC | 76,247 | $503.2K | 0.00% | +1,430+1.9% | Added |
| Standard Life Aberdeen plc | 75,000 | $495.0K | 0.00% | 00.0% | Unchanged |
| Soleus Capital Management, L.P. | 72,730 | $480.0K | 0.02% | +47,730+190.9% | Added |
| Centiva Capital, LP | 60,000 | $396.0K | 0.02% | +47,947+397.8% | Added |
| Boothbay Fund Management, LLC | 59,838 | $394.9K | 0.01% | 00.0% | Unchanged |
| Stonepine Capital Management, LLC | 53,460 | $352.8K | 0.31% | −24,729−31.6% | Reduced |
| AIGH Capital Management LLC | 51,000 | $336.6K | 0.07% | +1,677+3.4% | Added |
| Citadel Advisors LLC | 32,519 | $214.6K | 0.00% | +32,519 | New |
| Birchview Capital, LP | 20,000 | $132.0K | 0.08% | +20,000 | New |
| Morgan Stanley | 4,000 | $26.4K | 0.00% | +1,000+33.3% | Added |
| UBS Group AG | 2,512 | $16.6K | 0.00% | +2,495+14,676.5% | Added |
| GAMMA Investing LLC | 1,720 | $11.4K | 0.00% | −364−17.5% | Reduced |
| Rhumbline Advisers | 1,521 | $10.0K | 0.00% | −145−8.7% | Reduced |
| Barclays PLC | 1,300 | $8.58K | 0.00% | +1,300 | New |
| SBI Securities Co., Ltd. | 2 | $13 | 0.00% | −245−99.2% | Reduced |
| Royal Bank of Canada | 11 | $0 | 0.00% | +11 | New |
| ADAR1 Capital Management, LLC | 0 | $0 | 0.00% | −58,230−100.0% | Sold out |
| Resolute Capital Asset Partners LLC | 0 | $0 | 0.00% | −30,000−100.0% | Sold out |
| Simplify Asset Management Inc. | 0 | $0 | 0.00% | −17,448−100.0% | Sold out |